PL3884939T3 - Inhibitory dehydrogenazy 3-fosfoglicerynianowej i ich zastosowania - Google Patents
Inhibitory dehydrogenazy 3-fosfoglicerynianowej i ich zastosowaniaInfo
- Publication number
- PL3884939T3 PL3884939T3 PL21167434.6T PL21167434T PL3884939T3 PL 3884939 T3 PL3884939 T3 PL 3884939T3 PL 21167434 T PL21167434 T PL 21167434T PL 3884939 T3 PL3884939 T3 PL 3884939T3
- Authority
- PL
- Poland
- Prior art keywords
- dehydrogenase inhibitors
- phosphoglycerate dehydrogenase
- phosphoglycerate
- inhibitors
- dehydrogenase
- Prior art date
Links
- 108010038555 Phosphoglycerate dehydrogenase Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662305930P | 2016-03-09 | 2016-03-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3884939T3 true PL3884939T3 (pl) | 2024-02-26 |
Family
ID=59789738
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17764026T PL3426243T3 (pl) | 2016-03-09 | 2017-03-08 | Inhibitory dehydrogenazy 3-fosfoglicerynianowej i ich zastosowania |
| PL21167434.6T PL3884939T3 (pl) | 2016-03-09 | 2017-03-08 | Inhibitory dehydrogenazy 3-fosfoglicerynianowej i ich zastosowania |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17764026T PL3426243T3 (pl) | 2016-03-09 | 2017-03-08 | Inhibitory dehydrogenazy 3-fosfoglicerynianowej i ich zastosowania |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US10954220B2 (pl) |
| EP (2) | EP3884939B1 (pl) |
| CY (1) | CY1124338T1 (pl) |
| DK (1) | DK3426243T3 (pl) |
| ES (2) | ES2883328T3 (pl) |
| HR (1) | HRP20211220T1 (pl) |
| HU (1) | HUE055197T2 (pl) |
| LT (1) | LT3426243T (pl) |
| PL (2) | PL3426243T3 (pl) |
| PT (1) | PT3426243T (pl) |
| RS (1) | RS62271B1 (pl) |
| SI (1) | SI3426243T1 (pl) |
| WO (1) | WO2017156165A1 (pl) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3426243T (pt) | 2016-03-09 | 2021-08-19 | Raze Therapeutics Inc | Inibidores de 3-fosfoglicerato desidrogenase e utilizações dos mesmos |
| EP4234552A3 (en) | 2016-03-09 | 2023-10-18 | Raze Therapeutics, Inc. | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof |
| US11319295B2 (en) | 2017-10-09 | 2022-05-03 | Merck Sharp & Dohme Corp. | Substituted phenyloxetane and phenyltetrahydrofuran compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors |
| WO2019099294A1 (en) * | 2017-11-14 | 2019-05-23 | Merck Sharp & Dohme Corp. | Novel substituted biaryl compounds as indoleamine 2,3-dioxygenase (ido) inhibitors |
| AU2019387370A1 (en) | 2018-11-30 | 2021-06-10 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| EP4200281A4 (en) * | 2020-08-18 | 2024-09-25 | Hutchison Medipharma Limited | PYRIMIDINONE COMPOUNDS AND THEIR USES |
| KR20240021883A (ko) | 2021-06-16 | 2024-02-19 | 셀진 코포레이션 | 신경변성 질환의 치료를 위한 카르복실산 기를 포함하는 아제티디닐 화합물 |
| AU2023412464A1 (en) | 2022-12-19 | 2025-07-31 | Chiesi Farmaceutici S.P.A. | Phosphoglicerate dehydrogenase inhibitors for the treatment of fibrosis |
| WO2025125295A1 (en) | 2023-12-13 | 2025-06-19 | Chiesi Farmaceutici S.P.A. | Thieno-indole amide derivatives as phgdh inhibitors |
| WO2025125293A1 (en) | 2023-12-13 | 2025-06-19 | Chiesi Farmaceutici S.P.A. | Thienopyrimidylamine derivatives as phgdh inhibitors |
| WO2025125290A1 (en) | 2023-12-13 | 2025-06-19 | Chiesi Farmaceutici S.P.A. | Novel phosphoglicerate dehydrogenase inhibitors for the treatment of fibrosis |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| US5639600A (en) | 1994-08-05 | 1997-06-17 | The Regents Of The University Of California | Diagnosis and treatment of cell proliferative disease having clonal macrophage involvement |
| US7087648B1 (en) | 1997-10-27 | 2006-08-08 | The Regents Of The University Of California | Methods for modulating macrophage proliferation using polyamine analogs |
| EP1147214B1 (en) | 1999-01-13 | 2011-01-05 | The Research Foundation Of State University Of New York | A novel method for designing protein kinase inhibitors |
| OA12118A (en) | 1999-12-10 | 2006-05-04 | Pfizer Prod Inc | PyrroloÄ2,3-dÜpyrimidine compounds. |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| KR100833371B1 (ko) | 2001-04-27 | 2008-05-28 | 젠야쿠코교가부시키가이샤 | 헤테로시클릭 화합물 및 이를 유효 성분으로 하는 항종양제 |
| AR034897A1 (es) | 2001-08-07 | 2004-03-24 | Hoffmann La Roche | Derivados n-monoacilados de o-fenilendiaminas, sus analogos heterociclicos de seis miembros y su uso como agentes farmaceuticos |
| JP4623962B2 (ja) | 2001-10-22 | 2011-02-02 | ザ・リサーチ・ファウンデーション・オブ・ステイト・ユニバーシティ・オブ・ニューヨーク | タンパク質キナーゼおよびホスファターゼ阻害剤、それらを設計する方法、ならびにそれらを使用する方法 |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| MXPA05001766A (es) | 2002-08-14 | 2005-08-19 | Atugen Ag | Uso de proteina quinasa n beta. |
| WO2004089925A1 (en) | 2003-04-03 | 2004-10-21 | Semafore Pharmaceuticals, Inc. | Pi-3 kinase inhibitor prodrugs |
| ES2382377T3 (es) | 2003-05-30 | 2012-06-07 | Gemin X Pharmaceuticals Canada Inc. | Compuestos triheterocíclicos, composiciones, y métodos para tratar cáncer |
| WO2005007623A2 (en) | 2003-07-03 | 2005-01-27 | The Trustees Of The University Of Pennsylvania | Inhibition of syk kinase expression |
| LT2612862T (lt) | 2004-05-13 | 2017-01-25 | Icos Corporation | Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės delta inhibitoriai |
| TW200634003A (en) | 2004-12-22 | 2006-10-01 | Astrazeneca Ab | Chemical compounds |
| AR053992A1 (es) | 2004-12-22 | 2007-05-30 | Astrazeneca Ab | Compuestos quimicos con actividad anticancerosa, un procedimiento para su preparacion, su uso en la preparacion de medicamentos y composicion farmaceutica. |
| US7449458B2 (en) | 2005-01-19 | 2008-11-11 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
| ES2493466T3 (es) | 2005-05-12 | 2014-09-11 | Abbvie Bahamas Ltd. | Promotores de la apoptosis |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
| US7345178B2 (en) | 2005-08-04 | 2008-03-18 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| HRP20140975T1 (hr) | 2005-10-07 | 2014-11-21 | Exelixis, Inc. | Derivati n-(3-amino-hinoksalin-2-il)-sulfonamida i njihova uporaba kao inhibitora fosfatidilinozitol 3-kinaze |
| WO2007053452A1 (en) | 2005-11-01 | 2007-05-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| HUE028588T2 (hu) | 2005-12-13 | 2016-12-28 | Incyte Holdings Corp | Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| KR101533461B1 (ko) | 2006-04-26 | 2015-07-02 | 에프. 호프만-라 로슈 아게 | Ｐｉ３ｋ저해제로 유용한 티에노［3,2-ｄ］피리미딘 유도체 |
| US7838542B2 (en) | 2006-06-29 | 2010-11-23 | Kinex Pharmaceuticals, Llc | Bicyclic compositions and methods for modulating a kinase cascade |
| EP2529621B1 (en) | 2006-09-22 | 2016-10-05 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
| EA200970447A1 (ru) | 2006-11-03 | 2009-10-30 | АйАрЭм ЭлЭлСи | Соединения и композиции в качестве ингибиторов протеинкиназы |
| HUE029188T2 (en) | 2007-03-12 | 2017-03-28 | Ym Biosciences Australia Pty | Phenylamino-pyrimidine compounds and their use |
| US8394794B2 (en) | 2007-03-23 | 2013-03-12 | Regents Of The University Of Minnesota | Therapeutic compounds |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| CA2687764A1 (en) | 2007-05-25 | 2008-12-04 | Vertex Pharmaceuticals Incorporated | Ion channel modulators and methods of use |
| MY165582A (en) | 2008-03-11 | 2018-04-05 | Incyte Holdings Corp | Azetidine and cyclobutane derivatives as jak inhibitors |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| HUE035798T2 (en) | 2008-11-03 | 2018-05-28 | Syntarga Bv | CC-1065 analogues and conjugates |
| US9096579B2 (en) | 2012-04-20 | 2015-08-04 | Boehringer Ingelheim International Gmbh | Amino-indolyl-substituted imidazolyl-pyrimidines and their use as medicaments |
| WO2015150097A1 (en) * | 2014-04-04 | 2015-10-08 | Iomet Pharma Ltd | Indole derivatives for use in medicine |
| PT3426243T (pt) | 2016-03-09 | 2021-08-19 | Raze Therapeutics Inc | Inibidores de 3-fosfoglicerato desidrogenase e utilizações dos mesmos |
| EP4234552A3 (en) | 2016-03-09 | 2023-10-18 | Raze Therapeutics, Inc. | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof |
-
2017
- 2017-03-08 PT PT177640265T patent/PT3426243T/pt unknown
- 2017-03-08 PL PL17764026T patent/PL3426243T3/pl unknown
- 2017-03-08 EP EP21167434.6A patent/EP3884939B1/en active Active
- 2017-03-08 ES ES17764026T patent/ES2883328T3/es active Active
- 2017-03-08 SI SI201730882T patent/SI3426243T1/sl unknown
- 2017-03-08 PL PL21167434.6T patent/PL3884939T3/pl unknown
- 2017-03-08 HR HRP20211220TT patent/HRP20211220T1/hr unknown
- 2017-03-08 ES ES21167434T patent/ES2965264T3/es active Active
- 2017-03-08 WO PCT/US2017/021420 patent/WO2017156165A1/en not_active Ceased
- 2017-03-08 LT LTEP17764026.5T patent/LT3426243T/lt unknown
- 2017-03-08 EP EP17764026.5A patent/EP3426243B1/en active Active
- 2017-03-08 RS RS20211023A patent/RS62271B1/sr unknown
- 2017-03-08 US US16/082,659 patent/US10954220B2/en active Active
- 2017-03-08 DK DK17764026.5T patent/DK3426243T3/da active
- 2017-03-08 HU HUE17764026A patent/HUE055197T2/hu unknown
-
2021
- 2021-01-15 US US17/150,669 patent/US11634412B2/en active Active
- 2021-07-19 CY CY20211100651T patent/CY1124338T1/el unknown
-
2023
- 2023-03-01 US US18/115,942 patent/US20230312536A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RS62271B1 (sr) | 2021-09-30 |
| EP3426243A4 (en) | 2019-07-03 |
| EP3426243B1 (en) | 2021-05-19 |
| EP3426243A1 (en) | 2019-01-16 |
| PT3426243T (pt) | 2021-08-19 |
| WO2017156165A1 (en) | 2017-09-14 |
| US20230009122A1 (en) | 2023-01-12 |
| US10954220B2 (en) | 2021-03-23 |
| ES2883328T3 (es) | 2021-12-07 |
| EP3884939B1 (en) | 2023-10-25 |
| EP3884939C0 (en) | 2023-10-25 |
| HRP20211220T1 (hr) | 2021-10-29 |
| EP3884939A1 (en) | 2021-09-29 |
| US11634412B2 (en) | 2023-04-25 |
| US20230312536A1 (en) | 2023-10-05 |
| SI3426243T1 (sl) | 2021-11-30 |
| HUE055197T2 (hu) | 2021-11-29 |
| PL3426243T3 (pl) | 2021-10-04 |
| ES2965264T3 (es) | 2024-04-11 |
| DK3426243T3 (da) | 2021-07-19 |
| CY1124338T1 (el) | 2022-07-22 |
| LT3426243T (lt) | 2021-08-10 |
| US20190071431A1 (en) | 2019-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2015342774B2 (en) | EZH2 inhibitors and uses thereof | |
| IL265922A (en) | tyk2 inhibitors and uses thereof | |
| IL266109A (en) | tyk2 inhibitors and uses thereof | |
| IL271999A (en) | TYK2 inhibitors and uses thereof | |
| IL258636A (en) | Acc inhibitors and uses thereof | |
| EP3344624B8 (en) | Tyk2 inhibitors and uses thereof | |
| GB201605126D0 (en) | Inhibitors and their uses | |
| EP3110820A4 (en) | Tyk2 inhibitors and uses thereof | |
| PT3426243T (pt) | Inibidores de 3-fosfoglicerato desidrogenase e utilizações dos mesmos | |
| EP3177288A4 (en) | Prmt5 inhibitors and uses thereof | |
| EP3160477A4 (en) | Prmt5 inhibitors and uses thereof | |
| EP3160466A4 (en) | Prmt5 inhibitors and uses thereof | |
| EP3262049A4 (en) | Tyk2 inhibitors and uses thereof | |
| IL263949A (en) | Complement inhibitors and their uses | |
| EP3426244C0 (en) | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof | |
| IL246362A0 (en) | Novel glutaminase inhibitors | |
| SG10201911204WA (en) | Autotaxin inhibitors and uses thereof | |
| PL3621694T3 (pl) | Inhibitory lrrc33 i ich zastosowanie | |
| IL267238A (en) | The paranase inhibitors and their use | |
| IL254916B (en) | Inhibitors and their uses | |
| IL255530A (en) | Efflux-pump inhibitors and therapeutic uses thereof | |
| IL267243A (en) | The paranase inhibitors and their use | |
| IL251162A0 (en) | Monoamine oxidase-B inhibitors and rehabilitation | |
| HK1263283A1 (en) | Crmp2 sumoylation inhibitors and uses thereof | |
| GB201505971D0 (en) | Inhibitors and their uses |